JADE201 / Jade Biosciences - LARVOL DELTA

JADE201: anti-BAFF-R monoclonal antibody for autoimmune diseases (The Manila Times) - "Announced dosing began in the Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis; interim, biomarker-rich data expected in 2027 are anticipated to inform indication prioritization and a focused clinical development strategy."

P1 data • Trial status • Rheumatoid Arthritis

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Jade Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Jade Biosciences, Inc.

First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

JADE201: potentially best-in-class anti-BAFF-R monoclonal antibody for autoimmune diseases (GlobeNewswire) - "A first-in-human study initially evaluating JADE201 in patients with rheumatoid arthritis is expected to begin in the second quarter of 2026, with interim data anticipated in 2027."

First-in-human • New trial • Rheumatoid Arthritis

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases (GlobeNewswire) - "In non-human primate studies, JADE201 achieved dose-dependent BAFF receptor occupancy, sustained B cell depletion after a single subcutaneous dose, and demonstrated approximately a two-fold increase in half-life compared with ianalumab....Jade expects to initiate a first-in-human study evaluating JADE201 in patients with rheumatoid arthritis in the first half of 2026. The randomized, placebo-controlled, single ascending dose trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with biomarker-rich endpoints including BAFF-R occupancy, soluble BAFF levels, and B cell subpopulation profiling."

New molecule • New trial • Preclinical • Immunology • Rheumatoid Arthritis